← Back to Clinical Trials
Recruiting NCT06590285

NCT06590285 Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06590285
Status Recruiting
Phase
Sponsor Scripps Health
Condition GVHD
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2026-04-02
Primary Completion 2031-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
App-based Educational Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2026-04-02 with a primary completion date of 2031-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized, phase I/II, open-label study will investigate the efficacy and safety of an educational sleep intervention vs standard of care in adults undergoing alloHSCT. The randomization target in this pilot phase is 60 patients.

Eligibility Criteria

Inclusion Criteria: * Male or female patients aged 18 or older at the time of study informed consent. * Have plan to undergo alloHSCT from any donor source using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non-myeloablative, myeloablative and reduced intensity conditioning are eligible. * Patients have access to digital device capable of downloading study app * Patients able to read study documents and able to complete informed consent within the study app Exclusion Criteria: * Failed prior alloHSCT within the past 6 months

Contact & Investigator

Central Contact

Jake New, MD, PhD

✉ new.jacob@scrippshealth.org

📞 858-784-2701

Principal Investigator

Jake New, MD, PhD

PRINCIPAL INVESTIGATOR

Scripps Clinic

Frequently Asked Questions

Who can join the NCT06590285 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying GVHD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06590285 currently recruiting?

Yes, NCT06590285 is actively recruiting participants. Contact the research team at new.jacob@scrippshealth.org for enrollment information.

Where is the NCT06590285 trial being conducted?

This trial is being conducted at San Diego, United States.

Who is sponsoring the NCT06590285 clinical trial?

NCT06590285 is sponsored by Scripps Health. The principal investigator is Jake New, MD, PhD at Scripps Clinic. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology